Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice-Reference-Cited by-同舟云学术

Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice

Published:2017-12-29 Issue:1 Volume:2 Page:47-54
ISSN:2473-4039
Container-title:JBMR Plus
language:en
Short-container-title:JBMR Plus

Author:

Williams Diarra K¹,Parham Sean G²,Schryver Eric²,Akel Nisreen S²,Shelton R Shane²,Webber Jessica²,Swain Francis L²,Schmidt Jami²,Suva Larry J¹²,Gaddy Dana²³

Affiliation:

1. Department of Veterinary Physiology and Pharmacology; College of Veterinary Medicine and Biomedical Sciences; Texas A&M University; College Station TX USA

2. Department of Orthopaedic Surgery; Center for Orthopaedic Research; University of Arkansas for Medical Sciences; Little Rock AR USA

3. Department of Veterinary Integrative Biosciences; College of Veterinary Medicine and Biomedical Sciences; Texas A&M University; College Station TX USA

Funder

American Physiological Society

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbm4.10025/fullpdf

Reference34 articles.

1. Aneuploidy and skeletal health;Kamalakar;Curr Osteoporos Rep,2014

2. Maternal age specific risk rate estimates for Down syndrome among live births in whites and other races from Ohio and metropolitan Atlanta, 1970-1989;Huether;J Med Genet,1998

3. Endocrine and musculoskeletal abnormalities in patients with Down syndrome;Hawli;Nat Rev Endocrinol,2009